Indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2NWobiY
No comments:
Post a Comment